Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05536141 · ClinicalTrials.gov registry record · Phase 1

A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors

A Phase 1 study of Solid Tumors and Clear Cell Renal Cell Carcinoma, sponsored by Arcus Biosciences.

Recruiting
Registry status
Phase 1
Development phase
362
Enrollment target
20
Study locations

NCT05536141: Recruiting Phase 1 study of Solid Tumors and Clear Cell Renal Cell Carcinoma, sponsored by Arcus Biosciences.

NCT05536141 is a Phase 1 study of Solid Tumors and Clear Cell Renal Cell Carcinoma that is actively recruiting participants, run by Arcus Biosciences. The registered enrollment target is 362 participants, above the 282-participant average among 125 other Solid Tumors trials with a reported enrollment target (28% higher). The trial reports 20 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05536141, a Phase 1 study of Solid Tumors and Clear Cell Renal Cell Carcinoma, is actively recruiting participants, sponsored by Arcus Biosciences.

RECRUITING
Registry status
Phase 1
Development phase
362 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to evaluate the safety and tolerability of: * casdatifan when taken alone in participants with advanced solid tumor malignancies and clear cell renal cell carcinoma (ccRCC) during the dose escalation stage; and * casdatifan monotherapy and casdatifan in combination with cabozantinib or zimberelimab or zimberelimab and ipilimumab in participants with ccRCC in the dose expansion stage.

Conditions Studied

Solid Tumors Clear Cell Renal Cell Carcinoma

Interventions

  • DRUG Ipilimumab
  • DRUG Zimberelimab
  • DRUG Cabozantinib
  • DRUG casdatifan

Study Locations (20)

California

  • University of California at San Diego - San Diego
  • UCLA - Santa Monica

Michigan

  • Barbara Ann Karmanos Cancer Center - Detroit
  • Henry Ford Health System - Detroit

New York

  • Tisch Cancer Institute, Icahn Mount Sinai Hospital - New York
  • Memorial Sloan Kettering - New York

Ohio

  • University Hospitals Cleveland Clinical - Cleveland
  • Cleveland Clinic - Cleveland

Tennessee

  • Sarah Cannon - Nashville
  • Vanderbilt-Ingram Cancer Center - Nashville

Alabama

  • University of Alabama at Birmingham - Birmingham

Florida

  • University of Miami - Miami

Georgia

  • Emory University - Atlanta

Trial Details

FieldValue
Enrollment Target 362 participants
Start Date 2022-10-26
Est. Completion 2029-03
Phase Phase 1
Arcus Biosciences

25 total trials

What NCT05536141 shows while recruiting

NCT05536141 is an interventional study that assigns participants to a tested intervention. The registered 362 participants enrollment target is mid-sized for trials with a published cap, above the 282-participant average among 125 other Solid Tumors trials with a reported enrollment target (28% higher).

The record links to 2 conditions, with Solid Tumors appearing as the primary indexed condition, and to 4 interventions - of which Ipilimumab is the first listed.

NCT05536141 names 20 study sites across 15 states, led by California, Michigan, New York.

Frequently Asked Questions

What is clinical trial NCT05536141 about?

NCT05536141 is a clinical study titled "A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors". The purpose of this study is to evaluate the safety and tolerability of: * casdatifan when taken alone in participants with advanced solid tumor malignancies and clear cell renal cell carcinoma (ccRCC) during the dose escalation stage; and * casdatifan monotherapy and casdatifan in combination with...

What is the current status of trial NCT05536141?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 362 participants. The study started on 2022-10-26. Estimated completion is 2029-03.

What conditions does trial NCT05536141 study?

This clinical trial studies the following conditions: Solid Tumors, Clear Cell Renal Cell Carcinoma.

What interventions are being tested in trial NCT05536141?

The interventions under investigation include: Ipilimumab (DRUG), Zimberelimab (DRUG), Cabozantinib (DRUG), casdatifan (DRUG).

Who is sponsoring clinical trial NCT05536141?

This trial is sponsored by Arcus Biosciences, which has 25 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05536141 being conducted?

This trial has 20 study locations across Alabama, California, Florida, Georgia, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Solid Tumors

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05536141's enrollment target sits among peer trials

362 14th of 125 higher than 112 of 125 other Solid Tumors trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Solid Tumors trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04988555 · 362 participants · Phase 1

    A Study of DSP-5336 in Relapsed/Refractory AML/ ALL With or Without MLL Rearrangement or NPM1 Mutation

  • NCT06534983 · 362 participants · Phase 2

    A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran With Nivolumab Versus Nivolumab Alone in Participants With High-risk Muscle-invasive Urothelial Carcinoma (MIUC)

  • NCT06472245 · 363 participants · Phase 3

    Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor

  • NCT05533697 · 361 participants · Phase 1

    Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT05536141

Source: ClinicalTrials.gov NCT05536141, the US trial registry maintained by the National Library of Medicine. NCT05536141 (mid enrollment · wide site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.